Signal Transduction in Anaplastic Large Cell Lymphoma Cells (ALCL) Mediated by the Tumor Necrosis Factor Receptor CD30
暂无分享,去创建一个
[1] V. Diehl,et al. Characterization of a Novel Human Anaplastic Large Cell Lymphoma Cell Line Tumorigenic in SCID Mice , 2002, Leukemia & lymphoma.
[2] C. Schneider,et al. Pleiotropic Signal Transduction Mediated by Human CD30: A Member of the Tumor Necrosis Factor Receptor (TNFR) Family , 2002, Leukemia & lymphoma.
[3] S. Morris,et al. Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non‐hodgkin's lymphoma , 2001, British journal of haematology.
[4] E. Hildt,et al. CD30-mediated cell cycle arrest associated with induced expression of p21CIP1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299 , 2001, Oncogene.
[5] C. Duckett,et al. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. , 2000, Blood.
[6] S. Pileri,et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. , 2000, Blood.
[7] M. Kadin,et al. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. , 2000, The Journal of investigative dermatology.
[8] R. Junghans,et al. Anti-CD30 antibody–based therapy , 2000, Current opinion in oncology.
[9] L. Boise,et al. CD30 Signals Integrate Expression of Cytotoxic Effector Molecules, Lymphocyte Trafficking Signals, and Signals for Proliferation and Apoptosis1 , 2000, The Journal of Immunology.
[10] M. Werner,et al. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas , 2000, Leukemia.
[11] J. Inoue,et al. TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase1 , 2000, The Journal of Immunology.
[12] S. Hsu,et al. Autocrine Growth Regulation of CD30 Ligand in CD30-Expressing Reed-Sternberg Cells: Distinction Between Hodgkin's Disease and Anaplastic Large Cell Lymphoma , 2000, Laboratory Investigation.
[13] G. Cheng,et al. Membrane Localization of TRAF 3 Enables JNK Activation* , 2000, The Journal of Biological Chemistry.
[14] I. Scheffrahn,et al. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation. , 1999, Experimental hematology.
[15] M. Kadin,et al. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). , 1999, The American journal of pathology.
[16] Peter Scheurich,et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF‐R1 activation by endogenous membrane‐anchored TNF , 1999, The EMBO journal.
[17] G. Inghirami,et al. CD30 in normal and neoplastic cells. , 1999, Clinical immunology.
[18] H. Nakano,et al. Differential regulation of IκB kinase α and β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1 , 1998 .
[19] H. Nakano,et al. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[20] I. Herr,et al. Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.
[21] D. Longo,et al. In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. , 1995, Cancer research.
[22] G. Pizzolo,et al. CD30 ligation induces nuclear factor‐ϰB activation in human T cell lines , 1995, European journal of immunology.
[23] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[24] N. Copeland,et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF , 1993, Cell.
[25] H. Stein,et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease , 1992, Cell.
[26] K. Lennert,et al. Updated Kiel classification for lymphomas , 1989, The Journal of pathology.